FDA Clears Phase 1 Trial of ARV-110 for Advanced Prostate Cancer

FDA Clears Phase 1 Trial of ARV-110 for Advanced Prostate Cancer
The U.S. Food and Drug Administration has signed off on Arvinas' first Phase 1 clinical trial to evaluate ARV-110 as a therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). The trial, scheduled to begin by April, will investigate the safety and tolerability of ARV-110 in mCRPC patients whose disease progressed after being treated with a minimum of two standard of care therapies. Medicines that target the androgen receptor, such as Zytiga (abiraterone) and Xtandi (enzalutamide), are widely used for the treatment of advanced prostate cancer. But as happens with many medications, tumors often develop a resistance to these therapies. In some cases, resistance develops when cells produce a variant of the androgen receptor, called AR-V7, that lacks the domain targeted by current androgen receptor inhibitors. In other cases, cancer cells overproduce the androgen receptor. Either way, degrading this receptor seems like a promising approach for treating these cancers, and Arvinas set out to do just that. Using their PROTAC protein degradation platform — which tags disease-causing proteins for degradation — the company developed ARV-110. This compound delivers small molec
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *